Atwood & Palmer’s Neurocrine Biosciences NBIX Stock Holding History

Atwood & Palmer’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$843	Hold	5	–	–	﹤0.01%	460
2026 Q1	$659	Hold	5	–	–	﹤0.01%	494
2025 Q4	$710	Hold	5	–	–	﹤0.01%	469
2025 Q3	$702	Hold	5	–	–	﹤0.01%	467
2025 Q2	$629	Hold	5	–	–	﹤0.01%	492
2025 Q1	$553	Hold	5	–	–	﹤0.01%	422
2024 Q4	$683	Hold	5	–	–	﹤0.01%	448
2024 Q3	$577	Hold	5	–	–	﹤0.01%	448
2024 Q2	$689	Hold	5	–	–	﹤0.01%	421
2024 Q1	$690	Hold	5	–	–	﹤0.01%	399
2023 Q4	$659	Hold	5	–	–	﹤0.01%	384
2023 Q3	$563	Hold	5	–	–	﹤0.01%	382
2023 Q2	$472	Hold	5	–	–	﹤0.01%	384
2023 Q1	$507	Buy	+5	New	+$520	﹤0.01%	358

Other funds holding NBIX

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SCP

Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Atwood & Palmer's NBIX Position: Q2 2026 in Review

Atwood & Palmer held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 5 shares worth $843. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Atwood & Palmer first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. 352 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Atwood & Palmer held 5 shares of Neurocrine Biosciences worth $843 as of Q2 2026.
Atwood & Palmer left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Atwood & Palmer's portfolio in Q2 2026, its #460 holding.
Atwood & Palmer first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
352 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.